Endpoints News 9. Dez. 2025 #SABCS25: BioNTech, BMS unwrap Phase 2 data for PD-L1xVEGF-A bispecific in breast cancer
Endpoints News 9. Dez. 2025 #ASH25: Eli Lilly's Jaypirca makes first-line case, but ceiling may be capped
Endpoints News 8. Dez. 2025 FDA sets new, higher bar for CAR-T cancer treatments to prove superiority
Endpoints News 8. Dez. 2025 #ASH25: Will a biotech’s pivot away from obesity let it compete with Novartis in leukemia?
Endpoints News 8. Dez. 2025 Dyne says Duchenne drug succeeds in pivotal study, heads to FDA for approval
Endpoints News 8. Dez. 2025 Cogent’s mastocytosis drug continues momentum, helps treat sicker patients
Endpoints News 8. Dez. 2025 Day One was one of three parties interested in Mersana; Bihua Chen and Cormorant’s third SPAC
Endpoints News 8. Dez. 2025 #ASH25: Kura, Syndax detail data for rival menin inhibitors as both eye earlier use in AML
Endpoints News 8. Dez. 2025 Structure Therapeutics’ obesity pill stacks up with Novo and Lilly; Ascletis also reports early results
Endpoints News 7. Dez. 2025 #ASH25: Star Therapeutics details early data for blood disorder shot, weighs IPO
Endpoints News 6. Dez. 2025 #ASH25: AstraZeneca's dual-targeting CAR-T sees similar responses in Western patients as in China
Endpoints News 6. Dez. 2025 #ASH25: As one door closes for Regeneron’s lymphoma bispecific, another reopens